Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 390-395

  Pinazo, María Jeśus ^a   Guerrero, Laura ^b   Posada, Elizabeth ^a   Rodríguez, Elena ^a   Soy, Dolors ^b   Gascon, Joaquim ^a  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; BENZODIAZEPINE; DOMPERIDONE; ENALAPRIL; ENTECAVIR; GABAPENTIN; KETOCONAZOLE; LEVOTHYROXINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CHAGAS DISEASE; CHRONIC DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TRYPANOSOMA CRUZI; URTICARIA; VOMITING;

ADOLESCENT; ADULT; CHAGAS DISEASE; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROIMIDAZOLES; PROSPECTIVE STUDIES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84872015240     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01401-12     Document Type: Article

References (21)

1. Pan American Health Organization. 2006. Estimación cuantitativa de la enfermedad de Chagas en las Americas. Organización Panamericana de la Salud, Montevideo, Uruguay.
2. Gascon J, Bern C, Pinazo MJ. 2010. Chagas disease in Spain, the United States, and other non-endemic countries. Acta Trop. 115:22-27.
3. Prata A. 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1:92-100.
4. Schijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, Levin MJ, Freilij H. 2003. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J. Antimicrob. Chemother. 52:441-449.
5. de Andrade AL, Zicker de Oliveira FRM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-1413.
6. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am. J. Trop. Med. Hyg. 59:526-529.
7. Marin-Neto JA, Rassi Jr A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S. 2008. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J. 156:37-43.
8. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, Bertochi G, Armenti A. 2009. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev. Anti-Infect. Ther. 7:157-163.
9. Rodriques Coura J, de Castro SL. 2002. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97:3-24.
10. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A. 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Inter. Med. 144:724-734.
11. Raaflaub J, Ziegler WH. 1979. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Drug Res. 29:1611-1614.
12. Raaflaub J. 1980. Multiple-dose kinetics of the trypanosomicide benznidazole in man. Drug Res. 30:2192-2194.
13. Pinazo MJ, Munoz J, Posada E, López-Chejade P, Gallego M, Ayala E, del Cacho E, Soy D, Gascon J. 2010. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob. Agents Chemother. 54:4896-4899.
14. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC. 2007. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298:2171-2181.
15. World Health Organization. 2002. Control of Chagas' disease. World Health Organ. Tech. Rep. Ser. 905:1-109.
16. Guerrero L, Pinazo MJ, Posada E, Gascon J, Ribas J, Soy D. 2011. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease. Clin. Chem. Lab. Med. 49:77-82.
17. StataCorp. 2011. Stata, release 12: statistical software. StataCorp, College Station, TX.
18. Morilla MJ, Benavidez PE, Lopez MO, Romero EL. 2003. Liposomal benznidazole: a high-performance liquid chromatographic determination for biodistribution studies. J. Chromatogr. Sci. 41:405-409.
19. Altcheh J, Moscatelli G, Moroni S, Mastrantonio G, Marson E, Garcia-Bournissen F. 2012. Estudios farmacológicos de Benznidazol y Nifurtimox en niños y mujeres lactantes con enfermedad de Chagas, p 40-44. VIII Taller Sobre la Enfermedad de Chagas Importada, Barcelona, Spain.
20. Anderson KE. 1981. Pharmacokinetics of nitroimidazoles: spectrum of adverse reactions. Scand. J. Infect. Dis. 26:60-67.
21. Cancado JR. 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44:29-37.